Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Profit After Tax (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Profit After Tax for 6 consecutive years, with -$140.7 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 26.68% to -$140.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$274.4 million through Dec 2025, up 19.98% year-over-year, with the annual reading at -$274.4 million for FY2025, 19.98% up from the prior year.
  • Profit After Tax hit -$140.7 million in Q4 2025 for Lyell Immunopharma, down from -$38.8 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$8.4 million in Q4 2022 to a low of -$191.9 million in Q4 2024.
  • Historically, Profit After Tax has averaged -$64.3 million across 5 years, with a median of -$54.0 million in 2021.
  • Biggest five-year swings in Profit After Tax: soared 89.97% in 2022 and later plummeted 530.34% in 2023.
  • Year by year, Profit After Tax stood at -$83.7 million in 2021, then skyrocketed by 89.97% to -$8.4 million in 2022, then tumbled by 530.34% to -$52.9 million in 2023, then tumbled by 262.62% to -$191.9 million in 2024, then rose by 26.68% to -$140.7 million in 2025.
  • Business Quant data shows Profit After Tax for LYEL at -$140.7 million in Q4 2025, -$38.8 million in Q3 2025, and -$42.7 million in Q2 2025.